New LaunchMay 1, 2026, 08:07 AM
WW to Offer Novo Nordisk's Ozempic® Pill via Med+ for Type 2 Diabetes
AI Summary
WW International, Inc. announced it will begin offering access to Novo Nordisk's newly available Ozempic® pill (semaglutide) through its Med+ offering. This addition provides members with a once-daily GLP-1 option for adults with type 2 diabetes, supported by a clinically backed program. The company will assist members with insurance navigation, potentially reducing monthly prescription costs to as low as $25 for eligible individuals, and offers comprehensive support including tailored nutrition guidance and coaching.
Key Highlights
- WW International to offer Novo Nordisk's Ozempic® pill through its Med+ offering.
- Ozempic® pill is a once-daily GLP-1 option for adults with type 2 diabetes.
- Many eligible members can leverage insurance for monthly prescription costs as low as $25.
- Weight Watchers Med+ provides access to FDA-approved semaglutide with clinical support.
- Members receive tailored nutrition guidance, coaching, and a blood sugar tracker.
- Weight Watchers diabetes nutrition program showed a 0.75% reduction in HbA1c after 6 months.
- Partnership with Novo Nordisk aims to broaden patient access and support.